Gyanranjan Rout1, Baibaswata Nayak1, Arpan H Patel2, Deepak Gunjan1, Vishwajeet Singh3, Saurabh Kedia1. 1. Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India. 2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA. 3. Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Abstract
BACKGROUND/AIMS: Direct-Acting Antivirals (DAAs) are now the standard of care for management of Chronic Hepatitis C (CHC) infection. The aim of this study was to evaluate change in Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP) by transient elastography (FibroScan®) after completion of DAA therapy. METHODS: LSM and CAP were measured serially (baseline pre-treatment, at 12 weeks post therapy, and one year after completion of therapy) in a prospective cohort of 372 CHC patients treated with DAAs. Patients with at least two FibroScan measurements were included. RESULTS: The mean age was 38.1 ± 12.6 years; 58.3% males. Cirrhosis as defined by biopsy or fibroscan measurement (≥12.5) kPa was found in 25.5%. On paired analysis (n = 317), LSM (IQR) decreased from a baseline value 7.1 (5.3-13.8) kPa to 6.2 (4.8-11.2) kPa 12 weeks post therapy with a median decline 0.7 (-0.6-2.6) kPa, P < 0.001. Similarly, on paired analysis (n = 160), LSM decreased from baseline 6.9 (5.1-12.7) kPa to 6.1 (4.8-9.4) kPa after one year of treatment with median decline 0.9 (-0.6-3.2) kPa, P < 0.001. In contrast, on paired analysis (n = 317), CAP increased from baseline of 213.0 (180.0-254.5) dB/m to 225.0 (190.0-269.0) dB/m at 12 weeks post therapy with median increase 7.0 (-23.5-45.5), P = 0.001. Similarly, on paired analysis (n = 160), CAP increased from baseline of 210.0 (180.3-260.8) dB/m to 234.0 (204.0-282.0) dB/m at one year post therapy with median increase 25.0 (-12.5-61.5) dB/m, P < 0.001. On multivariate linear regression analysis, low baseline CAP value and low albumin were significantly associated with increase in CAP values. CONCLUSION: Treatment with DAAs reduces liver stiffness, but is associated with increase in hepatic steatosis.
BACKGROUND/AIMS: Direct-Acting Antivirals (DAAs) are now the standard of care for management of Chronic Hepatitis C (CHC) infection. The aim of this study was to evaluate change in Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP) by transient elastography (FibroScan®) after completion of DAA therapy. METHODS: LSM and CAP were measured serially (baseline pre-treatment, at 12 weeks post therapy, and one year after completion of therapy) in a prospective cohort of 372 CHC patients treated with DAAs. Patients with at least two FibroScan measurements were included. RESULTS: The mean age was 38.1 ± 12.6 years; 58.3% males. Cirrhosis as defined by biopsy or fibroscan measurement (≥12.5) kPa was found in 25.5%. On paired analysis (n = 317), LSM (IQR) decreased from a baseline value 7.1 (5.3-13.8) kPa to 6.2 (4.8-11.2) kPa 12 weeks post therapy with a median decline 0.7 (-0.6-2.6) kPa, P < 0.001. Similarly, on paired analysis (n = 160), LSM decreased from baseline 6.9 (5.1-12.7) kPa to 6.1 (4.8-9.4) kPa after one year of treatment with median decline 0.9 (-0.6-3.2) kPa, P < 0.001. In contrast, on paired analysis (n = 317), CAP increased from baseline of 213.0 (180.0-254.5) dB/m to 225.0 (190.0-269.0) dB/m at 12 weeks post therapy with median increase 7.0 (-23.5-45.5), P = 0.001. Similarly, on paired analysis (n = 160), CAP increased from baseline of 210.0 (180.3-260.8) dB/m to 234.0 (204.0-282.0) dB/m at one year post therapy with median increase 25.0 (-12.5-61.5) dB/m, P < 0.001. On multivariate linear regression analysis, low baseline CAP value and low albumin were significantly associated with increase in CAP values. CONCLUSION: Treatment with DAAs reduces liver stiffness, but is associated with increase in hepatic steatosis.
Entities:
Keywords:
AASLD, American Association for the Study of Liver Diseases; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; BMI, Body Mass Index; CAP, Controlled Attenuation Parameter; CHC, Chronic Hepatitis C; DAAs, Directly-Acting Antivirals; F0-4, METAVIR Fibrosis Stage 0 to 4; Fibroscan; HCV, Hepatitis C Virus; HIV, Human Immunodeficiency Virus; IFN, Interferon; IQR, Interquartile Range; LSM, Liver Stiffness Measurement; NAFLD, Non-alcoholic Fatty Liver Disease; SD, Standard Deviation; SVR12; SVR12, Sustained Viral Response at 12 Weeks; TE, Transient Elastography; controlled attenuation parameter; liver stiffness measurement
Authors: Thierry Poynard; Victor de Ledinghen; Jean Pierre Zarski; Carol Stanciu; Mona Munteanu; Julien Vergniol; Julie France; Anca Trifan; Gilles Le Naour; Jean Christophe Vaillant; Vlad Ratziu; Frederic Charlotte Journal: J Hepatol Date: 2011-09-01 Impact factor: 25.083
Authors: Jessica A Davila; Robert O Morgan; Yasser Shaib; Katherine A McGlynn; Hashem B El-Serag Journal: Gastroenterology Date: 2004-11 Impact factor: 22.682
Authors: Anna S Lok; James E Everhart; Raymond T Chung; Hae-Young Kim; Gregory T Everson; John C Hoefs; Joel K Greenson; Richard K Sterling; Karen L Lindsay; William M Lee; Adrian M Di Bisceglie; Herbert L Bonkovsky; Marc G Ghany; Chihiro Morishima Journal: Hepatology Date: 2009-06 Impact factor: 17.425
Authors: Robert J Fontana; Herbert L Bonkovsky; Deepa Naishadham; Jules L Dienstag; Richard K Sterling; Anna S F Lok; Grace L Su Journal: Clin Gastroenterol Hepatol Date: 2008-11-07 Impact factor: 11.382